Wednesday, February 10, 2010, 2:47PM AEST - The Australian Stockmarket closes in 1 hour and 18 minutes.
To create a watchlist or portfolio of shares, Register

Par Pharmaceutical Companies Inc. (PRX)

 8:03AM AEST: 24.07 USD  Down 1.32 (5.20%)  
 MORE ON PRX 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 PHARMACUTICAL CO (NYSE:PRX) Delayed quote dataEdit
Last Trade:24.07 USD
Trade Time: 8:03AM AEST
Change:Down 1.32 (5.20%)
Prev Close:25.39
Open:25.41
Bid:N/A
Ask:N/A
1y Target Est:28.29
Day's Range:23.09 - 25.52
52wk Range:8.57 - 27.93
Volume:1,919,963
Avg Vol (3m):502,752
Market Cap:838.09M
P/E (ttm):21.55
EPS (ttm):1.12
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add PRX to Portfolio   Download Data

 HEADLINES 
•InPlay: Volume Alert -- Par Pharmaceutical breaks to fresh opening lows on a pick up in relative volume, losing over $1.70 during the past 10 mins as it dips down into the 23.00 area
Briefing.com (Wed 2:18AM)
•[video] Successfactors' Roller Coaster
at Forbes.com (Sat, Feb 6)
•UPDATE - Par Pharma unit says FDA declines nausea drug approval
at Reuters (Sat, Feb 6)
•Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
PR Newswire (Sat, Feb 6)
•Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2009 Results on February 24, 2010
PR Newswire (Wed, Feb 3)
•Improving Visibility on Watson
Zacks.com (Thu, Jan 28)
•3 Small Caps With Rocketing Shares
at SmartMoney.com (Fri, Jan 15)
•Watson Set to Beat Expectations
Zacks.com (Fri, Jan 15)
•The Put/Call Edge Plus 3 PowerRatings Stocks
TradingMarkets.com (Thu, Jan 14)
•Neutral on Watson
Zacks.com (Sat, Jan 9)
•Sector Snap: Generic drugmakers downgraded
AP (Sat, Jan 9)
•Time for U.K. Biotech to Scale Up -- or Die
at The Wall Street Journal Online (Fri, Jan 8)
•Neutral on Santarus
Zacks.com (Thu, Jan 7)
•MonoSol Rx and Strativa Pharmaceuticals Extend Strategic Relationship
PR Newswire (Wed, Jan 6)
•According To Credit Suisse Vice President, Certain Health Care Stocks To Benefit Greatly From U.S. Legislation: Which Companies Stand To Benefit The Most?
Wall Street Transcript (Tue, Dec 22)
More Headlines for PRX...
 ANALYST 
EPS Est (next year) (Dec-09) :2.48
EPS Est (in 2 years) (Dec-10) :1.64
Avg Rec (current)*:2.1
PEG Ratio:0.20
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices